With the emergence of numerous new variants of the novel coronavirus, it has become increasingly crucial to have accurate diagnostics that can detect multiple strains of the coronavirus. Pluslife Biotech has stepped up to the challenge with its cutting-edge SARS-CoV-2 test card that has the capacity to detect all common variants in 7-35 minutes, revolutionizing the field of SARS-CoV-2 diagnostics.

Multi-Variant Coronavirus Detection 

Pluslife Biotech has re-analyzed the alignment results of the detection target regions of the SARS-CoV-2 Nucleic Acid Testing Card and the SARS-CoV-2/Flu A/Flu B Nucleic Acid Test Card. The findings confirm that these test cards can accurately detect the novel coronavirus and its reported mainstream variants, including Alpha, Beta, Gamma, Delta, and Omicron, as well as those labeled as "Variants of Concern" (VOC) by the World Health Organization (WHO). Importantly, these test cards do not produce false-negative results or encounter off-target issues.

Pluslife's Solution to SARS-CoV-2 Diagnosis

Pluslife Biotech stands at the forefront of the battle against SARS-CoV-2 and influenza. The innovative SARS-CoV-2 Nucleic Acid Testing Card and SARS-CoV-2/Flu A/Flu B Nucleic Acid Test Card represent a significant leap forward in the field of respiratory diagnostics. In the future, we will continue to closely monitor the latest developments in global variants of the novel coronavirus and update the latest viral information including the mutations and substitutions of SARS-CoV-2 to ensure the accuracy and sensitivity of our products.